Funk Ryan S, Singh Rakesh K, Winefield Robert D, Kandel Sylvie E, Ruisinger Janelle F, Moriarty Patrick M, Backes James M
a Department of Pharmacy Practice , University of Kansas Medical Center , Kansas City , KS , USA.
b Department of Pharmacology, Toxicology, and Therapeutics , University of Kansas Medical Center , Kansas City , KS , USA.
J Diet Suppl. 2018 May 4;15(3):343-351. doi: 10.1080/19390211.2017.1347227. Epub 2017 Aug 9.
Berberine is an isoquinoline alkaloid plant extract that is widely available as a dietary supplement in the United States and has demonstrated efficacy in the treatment of type 2 diabetes mellitus and dyslipidemia. Because of its increased use and purported pharmacological properties, potential variations in product quality could pose a barrier to berberine's safety and effectiveness in clinical practice. Thus, this study evaluated the potency of dietary supplements containing berberine available in the U.S. commercial market. Fifteen unique dietary supplements containing berberine were purchased through U.S. dietary supplement vendors. For each product, berberine was extracted from 3 unique capsules and analyzed by ultra-high-performance liquid chromatography tandem mass spectrometry. Percentage content based on the product label claim was determined for each product. The average berberine content across the products was found to be 75% ± 25% of the product label claim, with product potency ranging from 33% to 100%. Nine of the 15 tested products (60%) failed to meet the potency standards of 90% to 110% of labeled content claim, as commonly required of pharmaceutical preparations by the U.S. Pharmacopeial Convention. Evaluation of the relationship between product cost and the measured potency failed to demonstrate an association between quality and cost. Variability in product quality may significantly contribute to inconsistencies in the safety and effectiveness of berberine. In addition, the quality of the berberine product cannot be inferred from its cost.
黄连素是一种异喹啉生物碱植物提取物,在美国作为膳食补充剂广泛可得,并且已证明对2型糖尿病和血脂异常具有治疗效果。由于其使用增加以及据称的药理特性,产品质量的潜在差异可能会对黄连素在临床实践中的安全性和有效性构成障碍。因此,本研究评估了美国商业市场上含黄连素膳食补充剂的效力。通过美国膳食补充剂供应商购买了15种含黄连素的独特膳食补充剂。对于每种产品,从3粒独特的胶囊中提取黄连素,并通过超高效液相色谱串联质谱法进行分析。确定了每种产品基于产品标签声明的百分比含量。发现所有产品中黄连素的平均含量为产品标签声明的75%±25%,产品效力范围为33%至100%。15种受试产品中有9种(60%)未达到美国药典大会对药品制剂通常要求的标签含量声明的90%至110%的效力标准。对产品成本与测得效力之间关系的评估未能证明质量与成本之间存在关联。产品质量的差异可能会显著导致黄连素安全性和有效性的不一致。此外,不能从黄连素产品的成本推断其质量。